Product Pathways - Apoptosis
XAF1 Antibody #12615
|12615S||100 µl (10 western blots)||---||In Stock||---|
|12615||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting, IP=Immunoprecipitation
Species predicted to react based on 100% sequence homology: Monkey.
Specificity / Sensitivity
XAF1 Antibody recognizes endogenous levels of total XAF1 protein. Unknown background bands are observed at 45, 70, and 85 kDa.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val210 of human XAF1 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Western blot analysis of extracts from 293T cells, mock transfected (-) or transfected with a construct expressing full-length human XAF1 isoform 1 (hXAF1; +) using XAF1 Antibody.
X-linked inhibitor of apoptosis (XIAP)-associated factor 1 (XAF1) is a zinc finger protein that antagonizes the anti-apoptotic activity of XIAP (1,2). XIAP, a member of the inhibitor of apoptosis (IAP) family, inhibits apoptosis by direct inhibition of caspases (3; reviewed in 4). XAF1 is widely expressed in normal tissues, with highest levels in the heart and ovary, but is mostly reduced in cancer lines (1,2). Expression of XAF1 can be induced by interferons via Stat transcriptional activity (5-7). The levels of XAF1 have been shown to be inversely correlated with p53, and p53 is directly responsible for inhibiting XAF1 transcription (8,9). A number of studies have shown that XAF1 can function as a tumor suppressor protein, and decreased levels of XAF1 are found in a variety of different cancers (10-13). Research studies suggest that expression of XAF1 may be a prognostic biomarker for some cancers (14-16).
- Fong, W.G. et al. (2000) Genomics 70, 113-22.
- Liston, P. et al. (2001) Nat Cell Biol 3, 128-33.
- Deveraux, Q.L. et al. (1997) Nature 388, 300-4.
- Goyal, L. (2001) Cell 104, 805-8.
- Leaman, D.W. et al. (2002) J Biol Chem 277, 28504-11.
- Sun, Y. et al. (2008) Cancer Lett 260, 62-71.
- Bai, Y. et al. (2008) J Biol Chem 283, 6832-42.
- Zhang, W. et al. (2010) Int J Oncol 36, 1031-7.
- Zou, B. et al. (2012) Mol Carcinog 51, 422-32.
- Byun, D.S. et al. (2003) Cancer Res 63, 7068-75.
- Ng, K.C. et al. (2004) J Invest Dermatol 123, 1127-34.
- Ma, T.L. et al. (2005) Chin J Dig Dis 6, 10-4.
- Zou, B. et al. (2006) Gastroenterology 131, 1835-43.
- Huang, J. et al. (2010) Cancer Sci 101, 559-67.
- Chen, Y.B. et al. (2011) Chin Med J (Engl) 124, 3238-43.
- Wang, Y. et al. (2012) Regul Pept 178, 36-42.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.